Bicycle Therapeutics plc (NASDAQ:BCYC) Expected to Post Earnings of -$0.66 Per Share


Share on StockTwits

Equities research analysts predict that Bicycle Therapeutics plc (NASDAQ:BCYC) will announce earnings of ($0.66) per share for the current fiscal quarter, Zacks Investment Research reports. Five analysts have provided estimates for Bicycle Therapeutics’ earnings. The lowest EPS estimate is ($0.88) and the highest is ($0.53). Bicycle Therapeutics reported earnings per share of ($0.63) in the same quarter last year, which suggests a negative year-over-year growth rate of 4.8%. The business is expected to announce its next quarterly earnings report on Thursday, May 6th.

On average, analysts expect that Bicycle Therapeutics will report full year earnings of ($2.99) per share for the current year, with EPS estimates ranging from ($4.27) to ($2.17). For the next financial year, analysts anticipate that the firm will post earnings of ($3.49) per share, with EPS estimates ranging from ($5.70) to ($2.74). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Bicycle Therapeutics.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its quarterly earnings data on Wednesday, March 10th. The company reported ($0.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.36). Bicycle Therapeutics had a negative net margin of 321.26% and a negative return on equity of 42.73%. The company had revenue of $3.85 million for the quarter, compared to analysts’ expectations of $3.24 million.

Several equities analysts have commented on BCYC shares. Zacks Investment Research raised shares of Bicycle Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, March 16th. Cantor Fitzgerald lifted their target price on shares of Bicycle Therapeutics from $30.00 to $58.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 20th. Oppenheimer boosted their price objective on shares of Bicycle Therapeutics from $27.00 to $38.00 and gave the company an “outperform” rating in a research report on Friday, January 15th. Finally, HC Wainwright upped their price target on shares of Bicycle Therapeutics from $28.00 to $31.00 and gave the stock a “buy” rating in a research report on Friday, January 15th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. Bicycle Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $38.00.

In related news, CFO Lee Kalowski sold 15,000 shares of the business’s stock in a transaction on Tuesday, January 19th. The shares were sold at an average price of $30.00, for a total value of $450,000.00. Following the transaction, the chief financial officer now owns 15,000 shares in the company, valued at $450,000. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Pierre Legault sold 24,838 shares of the business’s stock in a transaction on Thursday, April 8th. The shares were sold at an average price of $31.71, for a total transaction of $787,612.98. Following the completion of the transaction, the director now owns 24,838 shares in the company, valued at approximately $787,612.98. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 75,000 shares of company stock valued at $2,263,838. Corporate insiders own 26.30% of the company’s stock.

Several large investors have recently bought and sold shares of the company. Renaissance Technologies LLC grew its position in Bicycle Therapeutics by 36.5% in the 4th quarter. Renaissance Technologies LLC now owns 81,200 shares of the company’s stock worth $1,458,000 after purchasing an additional 21,700 shares in the last quarter. Victory Capital Management Inc. grew its holdings in shares of Bicycle Therapeutics by 11.5% during the 4th quarter. Victory Capital Management Inc. now owns 169,250 shares of the company’s stock valued at $3,038,000 after purchasing an additional 17,520 shares during the last quarter. Bank of New York Mellon Corp bought a new position in shares of Bicycle Therapeutics during the 4th quarter valued at $238,000. US Bancorp DE bought a new stake in Bicycle Therapeutics in the 4th quarter worth $235,000. Finally, Captrust Financial Advisors bought a new stake in Bicycle Therapeutics in the 4th quarter worth $54,000. 42.68% of the stock is owned by institutional investors.

BCYC stock traded down $1.35 during mid-day trading on Monday, reaching $28.10. The company’s stock had a trading volume of 98,853 shares, compared to its average volume of 180,682. The stock has a market cap of $648.83 million, a PE ratio of -13.57 and a beta of -0.21. The company has a current ratio of 9.63, a quick ratio of 9.63 and a debt-to-equity ratio of 0.13. Bicycle Therapeutics has a fifty-two week low of $12.54 and a fifty-two week high of $33.20. The company’s 50 day moving average is $27.13 and its two-hundred day moving average is $22.98.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease.

Featured Article: S&P/TSX Index

Get a free copy of the Zacks research report on Bicycle Therapeutics (BCYC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bicycle Therapeutics (NASDAQ:BCYC)

Receive News & Ratings for Bicycle Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicycle Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.